HC Wainwright Has Bearish Estimate for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for Harmony Biosciences in a report released on Wednesday, August 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $3.55 for the year, down from their prior forecast of $3.83. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q1 2026 earnings at $0.75 EPS, FY2026 earnings at $4.08 EPS and FY2027 earnings at $5.00 EPS.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The company had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%. Harmony Biosciences’s revenue was up 16.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.05 earnings per share.

Several other equities research analysts have also issued reports on HRMY. Truist Financial began coverage on Harmony Biosciences in a research note on Monday, July 21st. They set a “buy” rating and a $48.00 price objective for the company. UBS Group dropped their price objective on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Monday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $55.00 target price (up from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. Finally, The Goldman Sachs Group assumed coverage on Harmony Biosciences in a research note on Thursday, July 10th. They set a “neutral” rating and a $33.00 price target for the company. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $34.19 on Monday. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 11.03, a P/E/G ratio of 0.40 and a beta of 0.84. Harmony Biosciences has a 52-week low of $26.47 and a 52-week high of $41.61. The stock has a fifty day moving average of $34.16 and a 200 day moving average of $33.78. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds have recently added to or reduced their stakes in HRMY. JPMorgan Chase & Co. lifted its stake in Harmony Biosciences by 2.4% during the fourth quarter. JPMorgan Chase & Co. now owns 235,882 shares of the company’s stock worth $8,117,000 after purchasing an additional 5,454 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Harmony Biosciences by 7.0% in the fourth quarter. Franklin Resources Inc. now owns 31,869 shares of the company’s stock worth $1,097,000 after buying an additional 2,096 shares during the period. Geode Capital Management LLC increased its holdings in shares of Harmony Biosciences by 22.8% in the fourth quarter. Geode Capital Management LLC now owns 902,934 shares of the company’s stock worth $31,077,000 after buying an additional 167,516 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of Harmony Biosciences by 2.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 53,826 shares of the company’s stock worth $1,852,000 after buying an additional 1,321 shares during the period. Finally, FMR LLC increased its holdings in shares of Harmony Biosciences by 1.9% in the fourth quarter. FMR LLC now owns 5,329,902 shares of the company’s stock worth $183,402,000 after buying an additional 101,182 shares during the period. Institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.